HLA-C*06:02 in Danish patients with psoriasis and response to biological treatment.

Mie Siewertsen Bergmann, Nikolai Loft, Christopher Willy Schwarz, Diljit Kaur-Knudsen, Claus Zachariae, Lone Skov
{"title":"HLA-C*06:02 in Danish patients with psoriasis and response to biological treatment.","authors":"Mie Siewertsen Bergmann, Nikolai Loft, Christopher Willy Schwarz, Diljit Kaur-Knudsen, Claus Zachariae, Lone Skov","doi":"10.1111/1346-8138.17415","DOIUrl":null,"url":null,"abstract":"<p><p>Whether clinical and genetic markers can be used to differentiate patients with varying responses to different psoriasis therapies needs to be elucidated. Here, we assess whether human leukocyte antigen C (HLA-C)*06:02 is associated with response to biologics. Response to treatment was defined as a Psoriasis Area and Severity Index score of ≤2 (PASI≤ 2) after 3 months. In total, 648 patients with psoriasis initiating treatment with biologics were included; 289 were HLA-C*06:02 positive and 359 were HLA-C*06:02 negative. Patients were treated with tumor necrosis factor (TNF) inhibitors (n = 469), interleukin (IL)-12/23 inhibitors (n = 92), IL-17 inhibitors (n = 78), and IL-23 inhibitors (n = 9). Significantly more patients positive for HLA-C*06:02 achieved PASI≤ 2 compared with patients negative for HLA-C*06:02 when treated with IL-12/23 inhibitors. There was no significant difference between response in HLA-C*06:02 positive and negative patients for TNF inhibitors or IL-17 inhibitors. No analyses were conducted for IL-23 inhibitors because of the limited number of patients. The data confirm that HLA-C*06:02 may be used as a biomarker for response to anti-IL12/23 treatment.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/1346-8138.17415","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Whether clinical and genetic markers can be used to differentiate patients with varying responses to different psoriasis therapies needs to be elucidated. Here, we assess whether human leukocyte antigen C (HLA-C)*06:02 is associated with response to biologics. Response to treatment was defined as a Psoriasis Area and Severity Index score of ≤2 (PASI≤ 2) after 3 months. In total, 648 patients with psoriasis initiating treatment with biologics were included; 289 were HLA-C*06:02 positive and 359 were HLA-C*06:02 negative. Patients were treated with tumor necrosis factor (TNF) inhibitors (n = 469), interleukin (IL)-12/23 inhibitors (n = 92), IL-17 inhibitors (n = 78), and IL-23 inhibitors (n = 9). Significantly more patients positive for HLA-C*06:02 achieved PASI≤ 2 compared with patients negative for HLA-C*06:02 when treated with IL-12/23 inhibitors. There was no significant difference between response in HLA-C*06:02 positive and negative patients for TNF inhibitors or IL-17 inhibitors. No analyses were conducted for IL-23 inhibitors because of the limited number of patients. The data confirm that HLA-C*06:02 may be used as a biomarker for response to anti-IL12/23 treatment.

丹麦银屑病患者的 HLA-C*06:02 与对生物治疗的反应。
临床和遗传标记是否可用于区分对不同银屑病疗法有不同反应的患者,这一点还有待进一步阐明。在此,我们评估了人类白细胞抗原C(HLA-C)*06:02是否与对生物制剂的反应相关。治疗反应的定义是 3 个月后银屑病面积和严重程度指数评分≤2(PASI≤ 2)。共纳入了648名开始接受生物制剂治疗的银屑病患者;其中289人HLA-C*06:02阳性,359人HLA-C*06:02阴性。患者接受了肿瘤坏死因子 (TNF) 抑制剂(469 例)、白细胞介素 (IL)-12/23 抑制剂(92 例)、IL-17 抑制剂(78 例)和 IL-23 抑制剂(9 例)的治疗。与HLA-C*06:02阴性的患者相比,接受IL-12/23抑制剂治疗的HLA-C*06:02阳性患者中达到PASI≤2的人数明显增多。HLA-C*06:02阳性和阴性患者对TNF抑制剂或IL-17抑制剂的反应无明显差异。由于患者人数有限,没有对 IL-23 抑制剂进行分析。这些数据证实,HLA-C*06:02可作为抗IL12/23治疗反应的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信